Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C Infection
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
The purpose of this study is to compare the safety and tolerability of ascending doses of SB 9200 given for up to 14 days to subjects with chronic Hepatitis C infection.
- Trial name
- NCT01803308
- Testing
- SB9200
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 37 people
- Sponsor
- Syneos Health
Chronic Hepatitis C
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection
- Trial name
- NCT00546715
- Testing
- Daclatasvir
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- Bristol-Myers Squibb
HIV, Hepatitis C
Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France
To evaluate the efficacy of a new screening for infectious diseases: tuberculosis, HIV, HBV and HCV, based on risk factors questionnaires (TB screen for tuberculosis and TROD screen for HIV and hepatitis) amongst a population of…
- Conditions
- HIV, Hepatitis C, Hepatitis B, Tuberculosis
- Trial name
- STRADA (NCT02959684)
- Where
- 18 sites in France
- Volunteers
- 70,000 people, healthy volunteers welcome
- Sponsor
- University Paris 7 - Denis Diderot
Hepatitis C
Antiviral Activity of AZD7295 in HCV Carriers
PK, safety study of AZD7295 in HCV carriers
- Trial name
- NCT00781976
- Testing
- AZD7295
- Where
- New Zealand
- Volunteers
- 31 people
- Sponsor
- Arrow Therapeutics
Chronic Hepatitis C
A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study
This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.
- Trial name
- HEARTLAND (NCT03710252)
- Testing
- paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
- Volunteers
- 100 people
- Sponsor
- American Research Corporation
Chronic Hepatitis C
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02798315
- Volunteers
- 40 people
- Sponsor
- AbbVie
Chronic Hepatitis C
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment.
- Trial name
- NCT01817985
- Testing
- GS-5816
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Chronic Hepatitis c
The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects
The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects.
- Trial name
- NCT03811678
- Testing
- Kangdaprevir Sodium Tablet
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C
C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study
Today's mobile devices (especially smartphones) are powerful ways to communicate new information to medical researchers. For this study, researchers at Boston Children's Hospital are asking people with hepatitis C to make use of…
- Trial name
- CTracker (NCT02568540)
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Boston Children's Hospital
HCV Infection
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
Hepatitis C virus (HCV) is an enveloped, single strand, positive sense RNA flavivirus. Infection by HCV is typically chronic, although an estimated ~10-20% may spontaneously clear the virus.
- Trial name
- NCT03674125
- Testing
- GLS-6150
- Where
- 2 sites in South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Hepatitis C, Chronic
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)
This study is being done to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of MK-8325 in male hepatitis C virus (HCV)-infected participants. There will be 3 parts to this study.
- Trial name
- NCT01554189
- Testing
- MK-8325
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV)…
- Trial name
- NCT01715415
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis c
Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults
The purpose of the LEAP-C (learning, experiencing and preparing for hepatitis C treatment) study is to see if a brief (4-week) small group intervention will help people with HIV/HCV co-infection make an informed decision about…
- Trial name
- LEAP-C (NCT01472354)
- Testing
- Leap-c group intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Chronic Hepatitis C, Genotype
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
The purposes of this study are: 1. To evaluate whether treatment with peginterferon and ribavirin for 24 weeks is sufficient to achieve a sustained virological response (SVR) rate comparable to that observed with the standard…
- Trial name
- NCT00629967
- Testing
- pegylated interferon alpha 2a and ribavirin, Pegylated interferon alfa-2a and ribavirin
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C
Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C
Investigation of the effects of the new Abbvie direct acting anti-viral (DAA) treatment of chronic viral hepatitis C infection on the macrophage specific activation marker soluble CD163, portal hypertension determined by the…
- Trial name
- NCT02526641
- Testing
- Functional Hepatic Nitrogen Clearance (FHNC), Galactose Elimination Capacity (GEC), Liver vein catheterization
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- University of Aarhus
HCV Coinfection
Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B
HCV infection is one of the most prevalent etiologies for liver cirrhosis and hepatocellular carcinoma. HCV is highly heterogeneous, with seven confirmed major genotypes.
- Trial name
- NCT03050905
- Testing
- VEKIRAX, EXVIERA
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- HaEmek Medical Center, Israel
Compensated Cirrhosis
Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV
This study will evaluate the safety and efficacy of combination treatment with grazoprevir + elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and genotype 6 (GT6) hepatitis C virus (HCV) infection…
- Trial name
- NCT03037151
- Testing
- Grazaoprevir/Elbasavir, Grazaoprevir/Elbasavir/RBV
- Where
- 2 sites in Thailand
- Volunteers
- 100 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Hepatitis C, Chronic, Liver Cirrhosis
Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)
The objective of the study is to evaluate the superiority of treatment with PegIntron and Rebetol over no antiviral therapy (control group) in subjects with chronic hepatitis C and type C compensated cirrhosis.
- Trial name
- NCT00811967
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and antiviral activity of multiple, ascending doses of ABT-267 (also known as ombitasvir) administered as two-day monotherapy followed by ABT-267…
- Trial name
- NCT01563536
- Testing
- ABT-267, ABT-450, ABT-333
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
The purpose of this study is to determine whether BMS-650032 and BMS-790052 in combination alone, together with Ribavirin, or together with Interferon and Ribavirin are effective in the treatment of Hepatitis C in patients who…
- Trial name
- NCT01012895
- Testing
- BMS-790052, BMS-650032, Pegylated-interferon alfa-2a
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 215 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.